c-Met expression and activity in urogenital cancers – novel aspects of signal transduction and medical implications

Ralf Hass†, Susanne Jennek‡, Yuanyuan Yang§ and Karlheinz Friedrich‡*

Abstract

C-Met is a receptor tyrosine kinase with multiple functions throughout embryonic development, organogenesis and wound healing and is expressed in various epithelia. The ligand of c-Met is Hepatocyte Growth Factor (HGF) which is secreted among others by mesenchymal stroma/stem (MSC) cells. Physiological c-Met functions are centred around processes that underly cellular motility and invasive growth. Aberrant c-Met expression and activity is observed in numerous cancers and makes major contributions to cell malignancy. Importantly, HGF/c-Met signaling is crucial in the context of communication between cancer cells and the the tumor stroma. Here, we review recent findings on roles of dysregulated c-Met in urogenital tumors such as cancers of the urinary bladder, prostate, and ovary. We put emphasis on novel aspects of cancer-associated c-Met expression regulation on both, HGF-dependent and HGF-independent non-canonical mechanisms. Moreover, this review focusses on c-Met-triggered signalling with potential relevance for urogenital oncogenesis, and on strategies to specifically inhibit c-Met activity.

Keywords: c-Met, HGF/SF signalling, c-Met inhibitors, MSC, Bladder, prostate and ovarian cancer

Background

c-Met (mesenchymal epithelial transition factor) is a multifunctional transmembrane tyrosine kinase and acts as a receptor for hepatocyte growth factor/Scatter factor (HGF/SF) [1]. It is expressed in various epithelial tissues (liver, pancreas, prostate, kidney, muscle, bone-marrow) during embryogenesis [2] and is also found on the cell surface of numerous tumorous cell populations. Shortly after its discovery, multiple oncogenetic properties of c-Met were described, including the stimulation of cell dissociation, migration, motility, and invasion of extracellular matrix [3–6]. Formation of mature c-Met is achieved by proteolytic cleavage of a precursor in a post-Golgi compartment, resulting in a small alpha and large beta polypeptide which then associate into a heterodimer. A disulfide bridge connects the small alpha unit and the extracellular segment of the membrane spanning beta subunit [7]. The extracellular part of the beta subunit is composed of an N-terminal sematophorin (sema) domain (essential for receptor activation) followed by a cysteine-rich portion (plexin sematophorin domain) and four IPT (immunoglobulin like plexins transcription factor) domains. A transmembrane helix connects the extracellular domain of c-Met to its intracellular section which can be divided into a juxtamembrane domain, a tyrosine kinase domain and the C-terminal region [2] (Figs. 1 and 2).

Structure and function of c-Met

C-Met becomes activated through homo-dimerisation upon binding of its ligand HGF [8–12]. As a result of ligand-induced dimerization, the intracellular tyrosine kinase domains of the two receptor beta-subunits trans-phosphorylate each other at residues Tyr1234 and Tyr1235 within the catalytic loops [13]. This event fully unleashes the tyrosine kinases which subsequently catalyze further phosphorylation of the receptor chain at Tyr1003 in the
juxtamembrane domain and Tyr$^{1349}$/Tyr$^{1356}$ within the C-terminal region (Fig. 1). These modifications relay further signals by generating specific contact interfaces (pTyr-containing motifs) with a variety of different src homology domain 2 (SH2) containing adaptor molecules to eventually regulate induction of cell motility, proliferation, invasiveness, and tubular morphogenesis [14–22].

C-Met receptor downstream signaling is mediated by recruitment of distinct adaptor and effector proteins such as src-homology-2- (SH2-), src-homology-3- (SH3-) domain-containing proteins and phospho-tyrosine-binding proteins (PTB) (Fig. 1). These adaptor proteins without enzymatic activity include Grb2 (growth factor receptor-bound protein 2), CRK ((CT10 (chicken tumor virus number 10) regulator of kinase)), and GAB1 (GRB2-associated binding protein 1). C-Met-binding proteins with enzymatic activity include Src kinases, PI3K (phosphatidylinositol 3-kinase), PLC-γ1 (phospholipase C-γ1), SHIP-2 (SH2 domain-containing 5’ inositol phosphatase), STAT-3 (signal transducer and activator of transcription), SOS (Ras guanine nucleotide exchange factor son-of-seven), PTPs (protein tyrosine phosphatases), e.g., SHP2 (SH2 domain-containing phosphatase-2) [14, 16–23]. HGF-stimulated c-Met activation can also phosphorylate downstream targets such as p44/42 MAP kinase (ERK) to mediate enhanced proliferation and cell cycle progression [2, 24, 25] (Fig. 1). In addition, Met can be activated even in the absence of HGF. In this context, Fan et al. described a novel HGF-independent mechanism in which non-receptor tyrosine kinase FER is involved. The upregulation of FER in ovarian cancers could trigger a signaling cascade downstream of c-Met in a HGF independent manner. Mechanistically, FER was shown to phosphorylate the tyrosine residue of the C-terminal SH2 domain docking site of c-Met, thus maintaining recruitment of signaling molecules such as GAB1 and Grb2 to the receptor. Most importantly, FER-mediated downstream signaling by c-Met could not be inhibited by a c-Met inhibitor alone [26].

**Intra- and intercellular signaling triggered by c-Met in urogenital cancers**

Activated c-Met in normal cells – predominantly in stromal cells including MSC - plays a major role in organogenesis and wound healing whereas in tumor cells, HGF-activated c-Met contributes to invasive and metastatic behavior [12, 27]. Various urogenital cancers like muscular-invasive urinary bladder cancer, prostate cancer and ovarian cancer express c-Met [28–30]. c-Met can be detected in about 70% of the different types of ovarian cancers such as low and high grade serous, endometrioid, clear cell and mucinous carcinomas, in
about 30% of the tumors c-Met is expressed to a noticeably high degree [31–33]. C-Met over-expression is observed particularly in hyperactive tumors which also show elevated angiogenesis and neo-vascularization due to activity of vascular endothelial growth factor receptor-2 (VEGF-R2). These tumor properties correlate with poor prognosis [34–36].

In prostate cancer, it was shown that androgen deprivation is connected with a more aggressive phenotype and leads to an increased c-Met expression. In parallel, the androgen receptor, which is known as a negative regulator of c-Met, is downregulated [37–39]. Hence, c-Met signaling obviously has an important role in maintaining survival as well as proliferation in androgen receptor-independent prostate cancer cells [40]. In this context, evidence has been obtained for an association of c-Met activation with decreased expression of genes related to DNA repair. It was, thus, suggested that c-Met may contribute to the accumulation of DNA damage and mutations and consequently favor progression of castration-resistant prostate cancer [40].

A recent report shows that c-Met upregulation in castration-resistant prostate cancer tissue is associated with a different distribution pattern compared to biopsies from naïve prostate cancer tissue. Interestingly, a c-Met fragment lacking the c-terminal part of full-length membranous c-Met was found to accumulate in the nuclei of
tumor cells preferentially in castration-resistant prostate cancer [41]. These results support the notion of a role for full-length and processed c-Met in the progression of androgen-independent prostate cancer.

Elevated c-Met expression in tumor cells also leads to enhanced c-Met activity within the tumor tissue, since profound HGF expression within the tumor stroma activates c-Met on cancer cells in a paracrine manner. HGF expression was shown to be clearly increased in urological cancers such as urinary bladder, prostate, and ovarian cancer [42–45]. In prostate and bladder cancer, c-Met-related feedback activation crosstalk between carcinoma cells and tumor-associated fibroblasts was characterized: HGF secretion becomes upregulated in stromal fibroblasts co-cultured with tumor cells, which in turn enhances migratory and invasive properties of cancer cells [44, 46–51]. However, in normal ovary HGF is mainly detected in the ovarian surface epithelium on the outer surface of the ovary and to a lesser extend in ovarian stromal cells directly adjacent to the ovarian surface epithelium [45]. Moreover, an elevated HGF expression is detectable in epithelial cell components of ovarian tumors and in MSC suggesting an autocrine and/or paracrine stimulation of ovarian tumor growth including tumor cell protection [45]. In other cancer entities such as gastric and colon cancer, HGF/c-Met signaling was shown to be operative in fibroblasts within the tumor microenvironment, thereby contributing to tumor progression [55, 56]. Moreover, immunohistochemical analysis showed c-Met expression on myofibroblasts mainly in the invasive area of lung adenocarcinoma [57]. c-Met expression on myofibroblasts in patients with small-sized lung adenocarcinoma was correlated with shortened patient survival [57]. It will be important to address in how far HGF-mediated fibroblast activation does also play a role in urogenital cancers.

### Non-canonical signaling by c-Met

It is now well established that receptor tyrosine kinases can also act via signaling pathways other than the Ras/Raf cascade. “Canonical signaling” is currently used as a term for the signaling route extending from ligand binding to the cell surface exodomains of receptors resulting in dimerization/oligomerisation and receptor trans-/auto-phosphorylation with subsequent intracellular signal release. Recently, “non-canonical signaling” has emerged as a concept to describe the specific generation of defined intracellular tyrosine kinase receptor fragments which have different functions [58]. The formation of these fragments is achieved by the activity of different proteases whose functions can be dependent or independent of receptor stimulation by ligand (Fig. 2).

Four cleavage products of c-Met with potential functions in signaling have as yet been described. The extracellular N-terminal fragment (Met-NTF) can be eliminated from the full-length receptor by metalloproteinases such as ADAM-10 and ADAM-17. Subsequent processing of the membrane-proximal C-terminal fragment (Met-CTF) by presenilin-dependent, regulated, intramembrane proteolysis (PS-RIP) results in an intracellular c-Met fragment (Met-ICD) which becomes subject to proteasomal degradation [59–62]. It is controversial as to whether the extracellular soluble domain of c-Met (NTF) exerts the physiological function of sequestering and, thus, antagonizing HGF/SF and is also a potent antagonist to the antagonist [63–65]. However, in mouse xenograft experiments with injected UOK261 bladder carcinoma cells, which show a high proteolytic cleavage rate of the full-length receptor, a linear relationship between soluble c-Met in the plasma or urine and total tumor volume was shown [63, 64]. Moreover, the level of soluble c-Met in urine from bladder cancer patients was shown to be a disease marker and to even allow for distinction between tumor stages as muscle non-invasive and invasive cancers [66]. These findings suggest that cleavage of c-Met plays a role in urinary bladder cancer progression.

By shedding the Met-NTF, the resulting fragments Met-NTF and CTF can also be lysosomally degraded. Ancot et al. published a model describing the fate and subcellular location of the receptor-derived breakdown products post processing of the full-length cell surface receptor by PS-RIP and its proteasomal degradation upon removal of Met-NTF. However, if c-Met is membrane-bound and internalized, it can also undergo intracellular proteolytic cleavage. This process gives rise to Met-NTF and Met-CTF, which can subsequently be degraded lysosomally. Thus, fragment Met-CTF escapes processing by PS-RIP when the cleavage takes place intracellularly [67]. Both shedding-induced degradation pathways are independent of receptor activation and may serve the function of preventing overexpression and “over-activation” of c-Met [60, 61, 67].

Experimental overexpression of a segment comprising only the intracellular segment of c-Met devoid of the extracellular domain in NIH3 Ts fibroblasts showed an elevated oncogenic potential with enhanced proliferation and invasiveness compared to control fibroblasts [68]. Interestingly, constitutively active c-Met fragments were detected in cell nuclei of an aggressive breast carcinoma cell line. They showed trans-activating activity in an experimental Gal4-based transactivation assay and appear to have a function in connection with spontaneous migratory behaviour of this cell line [69]. However, the absence of tumor suppressor Wwox plays a role here. Wwox is believed to possess regulatory functions in both controlling the stability of full-length c-Met and in the inhibition of the transactivation function of nuclear...
As already mentioned above, the nuclear Met-ICD level is higher in castration-resistant than in naïve prostate cancer. Withdrawal of androgens upregulates nuclear Met-ICD which in turn activates transcription factor SOX9 and the β-catenin/androgen receptor signaling pathway. In combination, this promotes cell transformation and three-dimensional tumor growth in castration-resistant prostate cancer [41]. These results suggest that proteolytically generated c-Met fragments that are not lysosomally or proteosomally degraded and thus, accumulate in the cell which can contribute to tumor progression. However, as yet little is known about the precise physiological or pathological mode of action and function of these fragments.

c-Met cleavage products are functional in the control of cell death and survival [70]. The receptor can be cleaved intracellularly at two distinct sites in response to stress stimuli. The resulting 40 kD cytosolic p40Met fragment, in contrast to the ligand-activated full-length receptor, acts pro-apoptotically via the mitochondrial permeabilization process of the intrinsic apoptotic pathway. Caspase-3 was identified as the responsible protease for the cleavage of c-Met [71–73].

Cleavage of c-Met yields the intracellular p40Met fragment, a membrane-bound p100Met fragment and, in addition, a peptide ten amino acid residues in length designated M10 and corresponding to C-terminal end of the receptor protein [74, 75]. The p100Met fragment encompassing the entire extracellular domain, is still membrane-bound and can act as a scavenger of HGF/SF, thereby serving as an inhibitor of the HGF/c-MET signal cascade [74]. M10 can block TGF-β-induced SMAD2 phosphorylation by interaction with SMAD2 and, thus, exerts antifibrotic effects [75].

The ratio of full-length c-Met and caspase-3 appears to have an influence on the extent of apoptosis in hepatocytes: High abundance of c-Met can suppress caspase-3 activity and thus, suppress apoptosis. Under conditions of a strong apoptotic stimulus, however, this inhibitory effect of c-Met on caspase-3 is overcome and cell death is no longer blocked [76].

Remarkably, caspase-3 is also active in non-apoptotic melanoma and glioblastoma cells as well as in invasive bladder cancer promoting tumor progression [77–79]. Mukai et al. published that cancer cells are able to react on apoptotic stimuli with a higher invasiveness through caspase activation [80]. Until now there is no evidence for a role of caspase-3 mediated cleavage of c-Met in this context. Moreover, c-Met also becomes cleaved in necrosis [81] whereby c-Met can be shed by metalloproteases as discussed above and instead of further processing by the γ-secretase complex, it becomes degraded by calcium-dependent proteases (calpains). This process gives rise to a 40 kDa Met fragment designated p40Met calpain which differs from the previously described p40Met caspase fragment in a few amino acids and its inability to promote apoptosis [81]. Moreover, the mutation R970C found in lung cancer within the juxtamembrane domain of c-Met promotes the calpain-dependent formation of a novel 45 kDa fragment p45Met, particularly in confluent cells [82]. Overexpression of p45Met in epithelial cells enhances HGF-mediated cell scattering and invasion without induction of tyrosine kinase activity of p45Met. This indicates an alternative mechanism besides activation of cell scattering by full length receptor [82]. In addition, ectopic expression of R970C variant of Met in the suspension cell line Ba/F3 did not show any transforming capacity, supporting that HGF treatment, proteolytic cleavage and cell confluence are probably necessary for cancer-related effects of this variant [83].

Analysis of Met-overexpressing tumor samples from patients with non-small cell lung cancer demonstrated the existence of all Met fragments suggesting a variety of cellular conditions within lung tumors [81]. However, little is known about the role of the different c-MET fragments in tumor progression so far.

Interestingly, not only c-Met can contribute to tumor progression in a ligand-independent manner. Tate et al. indicated a role for c-Met ligand HGF in prostate cancer in the absence of its receptor [84]. HGF induces cell adhesion and migration in a c-Met-negative prostate cancer cell line on the basis of a low-affinity interaction between its heparin-binding domain and nucleolin. Nucleolin is a nuclear protein which is known to localize also to the surface of cells. In this setting, it may link HGF and integrin function [84]. Low or high concentrations of HGF have been observed to exert distinct functions also on non-tumorigenic cells, leading to the postulation that HGF can elicit cellular effects in a c-Met-independent manner in parallel with or alternatively to “classical” c-Met/HGF signaling [85, 86].

Experimental and pharmacological interference with c-Met activity in urogenital cancer cells

The identification of prominent c-Met expression in certain urogenital tumors suggested that the HGF/SF – c-Met axis may serve as an attractive target to be included into chemotherapeutic regimens. Different approaches have been taken towards molecularly targeting c-Met and HGF such as (i) competitive interference with HGF/c-Met interaction, (ii) inhibition of the tyrosine kinase activity of c-Met, or (iii) blocking of activated c-Met downstream signaling mediators (Fig. 1). Accordingly, several preclinical studies indicated that inhibition of c-Met represents a promising therapeutic strategy paralleled by findings that c-Met overexpression has prognostic value in urogenital cancers, particularly in ovarian cancer.
Using an ovarian cancer mouse model, the orally available c-Met inhibitor PF-2341066 was successfully applied to reduce cell proliferation, adhesion and invasion as well as to induce apoptosis [87]. This small-molecule inhibitor shows specificity against c-Met and anaplastic lymphoma kinase (ALK) and reduced mouse tumor size paralleled by increased animal survival [88].

Another c-Met inhibitor, Crizotinib (PF-02341066), represents a designed tyrosine kinase inhibitor based on the core structure of the c-Met-inhibitor PHA 665752 in which some functional groups of the originating molecule (PHA 665752) were altered. As a result Crizotinib has stronger affinity for the ATP-binding pocket of the kinase domain within the c-Met receptor. Consequently, binding of ATP to the c-Met kinase domain and subsequent tyrosine phosphorylation of the receptor and signal mediators are blocked [89, 90]. Moreover, Crizotinib displays further inhibitory potential for the tyrosine kinase receptor ALK and ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) [91]. Crizotinib has, hence, been approved for the treatment of ALK-positive non-small cell lung carcinoma in the United States since August 2011. Studies employing a combination of Crizotinib together with PF-05212384 or gedatolisib were performed to additionally inhibit the phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway in the tumor cells. Results demonstrated superior anti-tumor effects of this combination compared to the individual agents. However, this combined treatment was also associated with the development of a gedatolisib-resistant subline, indicating increased expression of the multi-drug-resistant-1 gene [92].

The orally administrable tyrosine kinase inhibitor Foretinib (XL880, GSK1363089) exhibits a certain specificity and high affinity binding for both c-Met (IC50: 0.4 nM) and vascular epithelial growth factor receptor-2 (VEGF-R2/KDR) (IC50: 0.9 nM) [93]. This drug can also bind to a variety of other growth factor receptors, however, with significantly reduced binding affinities: PDGFRα (IC50: 3.6 nM), PDGFRβ (IC50: 9.6 nM), RON (IC50: 3 nM), c-KIT (IC50: 6.7 nM), FLT-3 (IC50: 3.6 nM) und TIE-2 (IC50: 1.1 nM) and low affinities to FGFR1 (IC50: 660 nM), und EGFR (IC50: 2.9 μM) [93–95]. An association of Foretinib with receptor tyrosine kinases is accompanied by a conformational change within the kinase structure and deprivation of enzymatic activity. Notably, Foretinib binding to its target tyrosine kinases receptors remains stable for at least 24 h [95].

Foretinib has also been demonstrated to block MAP kinase signaling and cell cycle progression during in vitro studies, substantiating this drug as a multi-target tyrosine kinase inhibitor [96]. Promising in vivo studies with significant Foretinib-mediated reduction of tumor size were performed in NSCLC [91], in lung metastases [93], and in Hedgehog medulloblastoma [97].

Potential effects of Foretinib as a multi-target tyrosine kinase inhibitor besides its specificity for c-Met are also focused on inhibition of VEGF-R2 signaling as an important pathway during angiogenesis and subsequent neo-vascularization. Here, Foretinib exhibits properties which primarily target the tumor microenvironment, thereby displaying dual anti-tumorigenic strategies. Promising effects of Foretinib in targeting VEGF-R2 signaling were achieved by an approximately 10-fold reduction in tumor size of tumors of the rare and aggressive small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), following tumor initiation by the two model cell lines SCCOHT-1 and BIN-67, respectively. MSC within the tumor microenvironment were shown to contribute to this outcome [52, 53, 67, 98, 99]. Supportive evidence of Foretinib’s anti-tumor activity through inhibition of c-Met- and VEGFR-2-mediated signal transduction was also demonstrated in further tumor models e.g. hepatocellular carcinoma [100], kidney cell carcinoma [101] and gastric carcinoma [102].

The tumor microenvironment plays a pivotal role for therapeutic approaches [103–105]. The importance simultaneously targeting tumor cells and the tumor microenvironment of urogenital cancers by anti-cancer drugs in is also underscored by results with DCC-2701 as a c-Met/TIE-2/VEGF-R inhibitor [106]. In the course of stroma–cancer cell interactions, human ovarian fibroblasts and MSC produced and secreted HGF, leading to elevated growth and migration of ovarian cancer cells coinciding with c-Met phosphorylation at Tyr1349. Tumor treatment with DCC-2701 was able to efficiently reduce the tumor burden in vivo by inhibition of c-Met phosphorylation and c-Met-mediated signaling, for cell growth and migration [106].

Conclusions
In summary, the abundance of c-Met expression and intracellular signaling in urogenital cancers may provide a selective molecular target for tumor therapeutic interventions. Moreover, multi-target c-Met tyrosine kinase inhibitors with the property to simultaneously affect cancer cells and the tumor microenvironment represent efficient and focused drugs to target urogenital cancers. In this context, it is important to note that cancer growth and metastasis of c-Met-positive urogenital cancers involves further stimuli besides HGF-binding and subsequent c-Met signaling since no anti-tumor effect was detectable in an ovarian cancer clinical trial after using a humanized IgG2 antibody directed against HGF (AMG-102), even though AMG-102 prevents HGF binding to c-Met and subsequent c-Met activation [107].
It is likely that the above-mentioned and not entirely understood non-canonical c-Met signaling mechanisms as well as c-Met-independent HGF activity are involved in this phenomenon.

Abbreviations

c-Met: Mesenchymal epithelial transition factor; CRK: CT10 (chicken tumor virus number 10) regulator of kinase; Gab1: Grb2-associated binding protein 1; Grb2: Growth factor receptor-bound protein 2; HGF: Hepatocyte growth factor; IPT: Immunoglobulin-like plexins transcription factor; MAPK: Mitogen activated protein kinase; MSC: Mesenchymal stroma/stem cells; mTOR: Mammalian target of rapamycin; NfkB: Nuclear factor kB; PI3K: Phosphatidylinositol 3-kinase; PLCγ1: Phospholipase C γ1; PTB: Phospho-tyrosine-binding proteins; PTPs: Protein tyrosine phosphatases; semaphoring: Sema; SF: Scatter factor; SH2: Src homology domain-2; SH3: Src homology-3 domain; SHIP-2: SH2 domain-containing 5 phosphatase; SOS: Ras guanine nucleotide exchange factor; STAT-3: Signal transducer and activator of transcription; VEGF-R2: Vascular endothelial growth factor receptor-2

Acknowledgements

The authors declare no financial, personal, or professional conflict of interest. All authors have critically read and approved this work. YY is supported by a postdoctoral fellowship from the DAAD and CSC. This work was supported by a grant from the Erich und Gertrud Roggenbuck-Stiftung for Cancer Research to RH.

Funding

This work was supported by a grant from the Erich und Gertrud Roggenbuck-Stiftung for Cancer Research to RH.

Availability of data and materials

Not applicable.

Author’s contributions

KF and RH drafted the manuscript. YY and SJ contributed literature search, detailed structure of the manuscript, and design of the figures. All authors critically read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interest.

Consent for publication

All authors have critically read and approved this work.

Ethical approval and consent to participate

Not applicable.

Author details

1Biochemistry and Tumor Biology Lab, Department of Gynecology, Hannover Medical School, Hannover, Germany. 2Institute of Biochemistry II, University Hospital Jena, Nonnenplan 2-4, D-07743 Jena, Germany.

Received: 10 January 2017 Accepted: 13 February 2017

Published online: 17 February 2017

References

1. Rubin JS, Bottaro DP, Aaronson SA. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim Biophys Acta. 1993;1155:357–71.
2. Organ SI, Tzao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3:57–19.
3. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH 3 T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A. 1994;91:4731–5.
4. Jefferis M, Rong S, Vande Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med (Berl). 1996;74:505–13.
5. Sachs M, Weidner KM, Brinkmann V, Walther I, Obermeier A, Ullrich A, Birchmeier W. Met, metastasis, and morphogenetic activity of epithelial growth factor tyrosine kinases. J Cell Biol. 1996;133:1095–107.
6. Otsuba T, Takayama H, Sharp R, Celli G, LaRochelle WI, Bottaro DP, Ellmore N, Viera W, Owens JW, Anver M, Merlino G. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 1998;58:1517–67.
7. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2002;2:289–300.
8. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatocarcinomatous rats. Biochem Biophys Res Commun. 1984;121:450–9.
9. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987;272:239–42.
10. Bottaro DP, Rubin JS, Faletto D, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251:802–4.
11. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narisman RH, Hartmann G, Zarnegar R, Michalopoulos GK, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 1991;10:2867–78.
12. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF, Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915–25.
13. Rodrigues GA, Park M. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene. 1994;9:19–27.
14. Weidner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol. 1993;121:145–54.
15. Graziani A, Gramaglia D, dalla Zonca P, Comoglio PM. Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchange. J Biol Chem. 1993;268:9165–8.
16. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994;77:261–71.
17. Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio PM. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 1998;391:285–8.
18. Pellici G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, Bardelli A, Panayotou G, Waterfield MD, Ponzetto C, Pellici PG, et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene. 1995;10:1631–8.
19. Fixman ED, Fournier TM, Kamikura DM, Naujokas MA, Park M. Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein. J Biol Chem. 1996;271:13116–22.
20. Garcia-Guzman M, Dolf F, Zeh K, Vuori K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1-Crk signaling complex formation. Oncogene. 1999;18:7775–85.
21. Lock LS, Royal I, Naujokas MA, Park M. Identification of an atypical Grb2 carboxy-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases. J Biol Chem. 2000;275:13536–45.
22. Sakkab D, Lewitzky M, Posern G, Schaepfer U, Sachs M, Birchmeier W, Feller SM. Signaling of hepatocyte growth factor/scatter factor (HGF) to the small G protein Rap1 via the large docking protein Gab1 and the adapter protein CRKL. J Biol Chem. 2000;275:10772–8.
23. Matsumoto R, Tsuda M, Wang L, Miashi N, Abe T, Kimura T, Tanino M, Nishihara H, Hida K, Ohba Y, et al. Adaptor protein CRK induces epithelial-mesenchymal transition and metastasis of bladder cancer cells through HGF/c-Met feedback loop. Cancer Sci. 2015;106:709–17.
24. Mhawech-Fauceglia P, Afkhami M, Pejovic T. MET/HGF signaling pathway in ovarian carcinoma: clinical implications and future direction. Patholog Res Int. 2012;2012:960327.
25. Blumenschein Jr GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol. 2012;30:3287–96.
26. Fan G, Zhang S, Gao Y, Greer PA, Tonks NK. HGF-independent regulation of MET and Gab1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer. Genes Dev. 2016;30:1542–57.
71. Tulane D, Deheuninck J, Lourenco FC, Lamberle F, Ji Z, Leroy C, Puchois E, Moumen A, Maina F, Mehlen P, Fafeur V. Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage. Mol Cell Biol. 2004;24:10328–39.

72. Foveau B, Leroy C, Ancot F, Deheuninck J, Ji Z, Fafeur V, Tulane D. Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor. Cell Death Differ. 2007;14:752–64.

73. Lefebvre J, Muharram G, Leroy C, Khrenouche Z, Montagne R, Ichim G, Atanelishvili I, Shirai Y, Akter T, Buckner T, Noguchi A, Silver RM, Bogatkevich H, Hass Z, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of the MET receptor efficiently induces apoptosis via the intrinsic pathway independently of its tyrosine kinase activity. Cell Death Dis. 2013;4:e877.

74. Deheuninck J, Foveau B, Goormachter G, Leroy C, Ji Z, Tulane D, Fafeur V. Caspase cleavage of the MET receptor generates an HGF interfering fragment. Biochem Biophys Res Commun. 2008;367:573–7.

75. Atanelyshvili I, Shirai Y, Akter T, Buckner T, Noguchi A, Shirai Y, Akter T, Buckner T, Noguchi A, Silver RM, Bogatkevich H, Hass Z, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of the MET receptor efficiently induces apoptosis via the intrinsic pathway independently of its tyrosine kinase activity. Cell Death Dis. 2013;4:e877.

76. Ma J, Zou C, Guo L, Seneviratne DS, Tan X, Kwon YK, An J, Bowser R, Burton PB, Anderson CJ, Corbishly CM. Caspase 3 and p27 as predictors of apoptosis. Cancer Res. 2004;64:6112–9.

77. Burton PB, Anderson CJ, Corbishly CM. Caspase 3 and p27 as predictors of apoptosis. Cancer Res. 2004;64:6112–9.

78. Gudjónsdóttir G, Grund K, Eckert A, Bock BC, Funke B, Macher-Goeppinger S, Sieber S, Herold-Mende C, Wiestler OD, Roth W. Basal caspase activity promotes migration and aggressiveness in glioblastoma cells. Mol Cancer Res. 2007;5:1232–40.

79. Liu YR, Sun B, Zhao XL, Gu Q, Liu ZY, Dong XY, Che N, Mo J. Basal caspase-3 activity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells. Melanoma Res. 2013;23:243–53.

80. Mukai M, Kusama T, Hamanaka Y, Koga T, Endo H, Tatsuta M, Inoue M. Cross-targeted inhibition of c-Met and vascular endothelial growth factor receptor 2. Cancer. 2010;12:3507–16.

81. Montagne R, Berbon M, Douillet L, Debrecz B, Leroy C, Delhem N, Porte H, Copin MC, et al. Necrosis- and apoptosis-related Met cleavages have divergent functional consequences. Cell Death Differ. 2015;16:486–94.

82. Montagne R, Baranzelli A, Muharram G, Catherine L, Lesalfie M, Vincents A, Khrenouche Z, Werkmeister E, Cortot AB, Tulane D. MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering. Oncotarget. 2017. doi:10.18632/oncotarget.14499.

83. R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering. Oncotarget. 2017. doi:10.18632/oncotarget.14499.

84. Faria CC, Golbourn BJ, Dubuc AM, Remike D, Aghihiotis S, Luck A, Sabha N, Olsten S, Wu X, et al. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. Cancer Res. 2015;75:134–46.

85. Otte A, Raurich P, Himmelmanns P, Park-Simon TW, van der Ohe J, Hass R. In vitro and in vivo therapeutic approach for a small cell carcinoma of the ova hypercalcaemic type using a SCCOHT-1 cellular model. Orphanet J Rare Dis. 2013;8:123–40.

86. Yang Y, Bucan V, Baerhe H, van der Ohe J, Otte A, Hass R. Acquisition of new tumor cell properties by MSC-derived exosomes. Int J Oncol. 2015;47:244–52.

87. Huyhn H, Ong R, Soo KC. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis. 2012;15:59–70.

88. Choueiri TK, Vaishampayan U, Rosenberg JE, Loghan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, et al. Phase II biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2015;33:181–8.

89. Shah MA, Wainberg ZA, Ferrari MC, D'Amico AV, Kubo W, Golbourn BJ, Dubuc AM, Remike D, Aghihiotis S, Luck A, Sabha N, Olsten S, Wu X, et al. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. Cancer Res. 2015;75:134–46.

90. Yang Y, Bucan V, Baerhe H, van der Ohe J, Otte A, Hass R. Acquisition of new tumor cell properties by MSC-derived exosomes. Int J Oncol. 2015;47:244–52.

91. Toyama K, Vaishampayan U, Rosenberg JE, Loghan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, et al. Phase II biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2015;33:181–8.

92. Shah MA, Wainberg ZA, Ferrari MC, D'Amico AV, Kubo W, Golbourn BJ, Dubuc AM, Remike D, Aghihiotis S, Luck A, Sabha N, Olsten S, Wu X, et al. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. Cancer Res. 2015;75:134–46.

93. Mandell K, Yang Y, Schambach A, Glage S, Otte A, Hass R. Mesenchymal stem cells directly interact with breast cancer cells and promote tumor cell growth in vitro and in vivo. Stem Cells. 2013;31:3114–27.

94. Yang Y, Otte A, Hass R. Human mesenchymal stromal/stem cells exchange membrane proteins and alter functionality during interaction with different tumor cell lines. Stem Cells. 2015;34:1205–22.

95. Melzer C, Yang Y, Hass R. Interaction of MSC with tumor cells. Cell Commun Signal. 2016;14:20.

96. Kwok Y, Smith BD, Zhou Y, Kaufman MD, Godwin AK, Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene. 2015;34:144–53.

97. Comoglio P, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and escape. Nat Rev Drug Discov. 2008;7:504–16.